Transcriptomics

Dataset Information

0

Rapid transcriptional changes of ROS1 fusion positive cells in response to crizotinib treatments


ABSTRACT: Despite the initial benefit of tyrosine kinase inhibitors targeting ROS1 fusion kinase in non-small cell lung cancer, the complete responses are rare and resistance ultimately develops from residual tumor cells. Although several acquired resistance mechanisms after disease progression have been reported, the adaptative resistance mechanism that contributes to residual diseases before the onset of acquired resistance is less clear. Cellular adaption through the signaling rewiring under primary oncogene inhibition is considered a major mechanism contributing to residual disease. To explore the rapid signaling reprogramming under acute ROS1 inhibition, we treated a panel of ROS1 fusion-positive cells, mostly derived in our lab, with crizotinib for 24 hours and profiled transcriptional changes by RNA-seq. Understanding the molecular mechanism that supports residual disease could help us better target and eliminate drug-tolerant cells, thus improving the responses to ROS1 targeted therapies.

ORGANISM(S): Homo sapiens

PROVIDER: GSE239844 | GEO | 2023/08/07

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2022-10-06 | GSE214715 | GEO
2023-09-12 | PXD036771 | Pride
2023-09-12 | PXD036772 | Pride
| PRJNA886729 | ENA
2024-04-05 | PXD031359 | Pride
2024-04-05 | PXD031690 | Pride
2024-04-05 | PXD031346 | Pride
| PRJNA1001050 | ENA
2016-01-15 | E-GEOD-65016 | biostudies-arrayexpress
2018-12-31 | GSE64569 | GEO